Market Overview

My goal is to be on stage with my computer and let you
see my screen and make sure you know what buttons to
press, where you’re getting in & out, how to calculate
risk, your targets — all of those things.
It’s real-life trading. Make sure you sign up!
- Jerremy Newsome
GET TICKETS

6 Valuable Pipeline Drugs With Upcoming Catalysts

Share:
6 Valuable Pipeline Drugs With Upcoming Catalysts

Heading into December, biotech stocks held up fairly well in 2018. Evaluate Pharma, a firm specializing in data-driven news and analysis in biotech, compiled a list of blockbuster drugs in the works with catalytic events expected sometime in 2019. Let's dig in.

VX-659, Tezacaftor, Ivacaftor Triple Combo&

Sponsor Company: Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)

Indication: Cystic fibrosis patients with one F508del mutation and one minimal function mutation, as well as patients with two F508del mutations.

Net Present Value: $14.4 billion

Current Status: data from two late-stage studies of this triple combo regimen released Nov. 27 showed improvement in lung function.

Catalyst: Potential NDA filing no later than mid-2019.

Vertex is also evaluating another triple combo regimen, namely VX-445, Tezacaftor and Ivacaftor, and said it will use the data readout from this combo due in Q1 and the results for the VX-659, Tezacaftor and Ivacaftor combo to decide which regimen should be submitted for potential regulatory approval.

Related Link: FDA Snubs Mallinckrodt's Abuse-Deterrent Opioid Reformulation

Liso-cell/JCAR017

Sponsor Company: Celgene Corporation (NASDAQ: CELG)

Indication: A CD-19 protein-targeting CAR T-cell therapy developed for B-cell lymphoma and leukemia.

Net Present Value: $8.5 billion.

Current Status: Preliminary results of a Phase 1/2 study dubbed TRANSCEND CLL 004 that evaluated JCAR017 in heavily pretreated CLL/SLL patients were presented at the ASH 2018 meeting in December. The results showed an 81-percent response rate and "undetectable" minimal residual disease in patients with both high-and standard-risk disease who had previously received Imbruvica.

Catalyst: The trial moves to Phase 2 portion in 2019.

Semaglutide Oral

Sponsor Company: Novo Nordisk A/S (NYSE: NVO)

Indication: Oral GLP-1 agonist for type 2 diabetes.

Net Present Value: $7.6 billion

Current Status: Headline results from the last global Phase 3a trial, dubbed PIONEER 6, released Nov. 23 demonstrated cardiovascular safety as well as a significant reduction in both CV and all-cause mortality in people with Type 2 diabetes who are at high cardiovascular risk.

Catalyst: regulatory filing in the U.S. and EU in the first half of 2019.

See also: Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates

Aducanumab

Sponsor Company: Biogen Inc (NASDAQ: BIIB)

Indication: mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's disease.

Net Present Value: $7.4 billion.

Current Status: the drug is being evaluated in two separate Phase 3 trials dubbed ENGAGE and EMERGE.

Catalyst: Phase 3 data due in late 2019/early 2020.

Aducanumab is an anti-beta-amyloid monoclonal antibody. Thirty six- and 48-month data from the ongoing long-term extension Phase 1b trial presented at a conference in late October showed the results were consistent with previously reported analysis of the study.

Efgartigimod/ARGX-113

Sponsor Company: argenx SE – ADR (NASDAQ: ARGX)

Indication: AGRX-113, or efgartigimod, is a first-in-class antibody fragment used to treat patients with severe autoimmune diseases associated with high level of pathogenic immunoglobin G antibodies. It is being evaluated for several indications such as multiple sclerosis, immune thrombocytopenia, myasthenia gravis, pemphigus vulgaris and chronic inflammatory demyelinating polyneuropathy.

Net Present Value: $6.5 billion.

Current Status: Detailed Phase 2 data for efgartigimod in patients with immune thrombocytopenia presented at the ASH 2018 conference in early December showed clinically meaningful improvements in platelet counts.

Catalyst: The immune thrombocytopenia program is likely to be advanced to a Phase 3 trial in 2019, and efgartigimod with a subcutaneous mode of administration is to be tested in a Phase 2 trial in 2019.

NKTR-214

Sponsor Company: Nektar Therapeutics (NASDAQ: NKTR)

Indication: Along with Bristol-Myers Squibb Co (NYSE: BMY)'s Opdivo or Opdivo/Yervoy, NKTR-214, Nektar's lead candidate, is evaluated in more than 20 indications across nine tumor types.

Net Present Value: $6.2 billion.

Current Status: New data from the PIVOT-02 Phase 1/2 presented at the 2018 Society for Immunotherapy of Cancer Annual Meeting showed NKTR-214 has the potential to lead to tumor clearance and tumor specific immunologic memory when combined with therapies with complementary mechanisms of action.

Catalyst: Further data from the PIVOT-02 study is expected in 2019.

NKTR-214 binds to the CD122 receptor on the surface of cancer-fighting immune cells in order to stimulate their proliferation.

Posted-In: Evaluate PharmaBiotech Health Care Previews FDA Top Stories Trading Ideas General Best of Benzinga

 

Related Articles (BIIB + ARGX)

View Comments and Join the Discussion!

Amazon Sets Holiday Shopping Records

Analyst: NeuroMetrix Benefits From Alternative Pain Management Trend